Journal Mobile Options
Table of Contents
Vol. 2, No. 6, 2002
Issue release date: 2002
Pancreatology 2002;2:519–527

Expression of Drug-Metabolizing Enzymes in the Pancreas of Hamster, Mouse, and Rat, Responding Differently to the Pancreatic Carcinogenicity of BOP

Ulrich A.B. · Standop J. · Schmied B.M. · Schneider M.B. · Lawson T.A. · Pour P.M.
aUNMC Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebr., USA; bDepartment of Visceral and Transplantation Surgery, University of Heidelberg, and cDepartment of Surgery, Rheinische Friedrich-Wilhelms-University, Bonn, Germany; dDepartment of Visceral and Transplantation Surgery, Inselspital, Bern, Switzerland; Departments of ePharmaceutical Sciences and fPathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebr., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Methods: N-nitroso-bis(2-oxopropyl)amine (BOP) induces pancreatic ductal adenocarcinoma in Syrian golden hamsters, but not in rats or mice. To examine whether this difference is due to the diversity in the presence and distribution of enzymes involved in the metabolism of BOP, the cellular expression of nine cytochrome P-450 isozymes (CYP1A1, CYP1A2, CYP2B6, CYP2C8,9,19, CYP2D1, CYP2E1, CYP3A1, CYP3A2, and CYP3A4) and of three glutathione S-transferase isozymes (GST-π, GST-α, and GST-µ) was investigated in the pancreas of hamsters, rats, and mice by immunohistochemistry. Results: We found a wide species variation in the presence and cellular localization of the enzymes and a lack of several enzymes, including GST-α in islets, CYP2B6, CYP2C8,9,19, CYP3A1 in acinar cells, and CYP3A4 in ductal cells, in the rat as compared with hamster and mouse. Conclusion: Although the results could not clarify the reasons for the species differences in the pancreatic carcinogenicity of BOP, the presence of most of the cytochrome P-450 isozymes in pancreatic islets of all three species highlights the important role of the islets in drug metabolism.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hirvonen A: Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 1999;107(suppl 1):37–47.
  2. Lewis DF, Ioannides C, Parke DV: Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ Health Perspect 1998;106:633–641.
  3. Ketterer B: Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988;202:343–361.
  4. Booth J, Boyland E, Sims P: An enzyme from rat liver catalysing conjugations with glutathione. Biochem J 1961;79:516–524.
  5. Jakoby WB: The glutathione S-transferases: A group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol 1978;46:383–414.
  6. Chasseaud LF: The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res 1979;29:175–274.
  7. Boyer TD: The glutathione S-transferases: An update. Hepatology 1989;9:486–496.
  8. Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK, Warholm M, Jornvall H: Identification of three classes of cytosolic glutathione transferase common to several mammalian species: Correlation between structural data and enzymatic properties. Proc Natl Acad Sci USA 1985;82:7202–7206.
  9. Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B: Theta, a new class of glutathione transferases purified from rat and man. Biochem J 1991;274(Pt 2):409–414.
  10. Awasthi YC, Sharma R, Singhal SS: Human glutathione S-transferases. Int J Biochem 1994;26:295–308.
  11. Scarpelli DG, Reddy JK, Longnecker DS (eds): Experimental Pancreatic Carcinogenesis. Boca Raton, CRC Press, 1986.
  12. Longnecker DS, Wiebkin P, Schaeffer BK, Roebuck BD: Experimental carcinogenesis in the pancreas. Int Rev Exp Pathol 1984;26:177–229.
  13. Pour PM: Experimental pancreatic cancer. Am J Surg Pathol 1989;13(suppl 1):96–103.
  14. Standop J, Schneider MB, Ulrich AB, Chauhan S, Moniaux N, Büchler MW, Batra SK, Pour PM: The pattern of xenobiotic-metabolizing enzymes in the human pancreas. J Toxicol Environ Health, in press.
  15. Pour PM, Kazakoff K, Dulany K: A new technique for simultaneous demonstration of 4 tumor-associated antigens in pancreatic cancer cells. Zentralbl Pathol 1994;140:397–401.
  16. Pour P, Salmasi S, Runge R, Gingell R, Wallcave L, Nagel D, Stepan K: Carcinogenicity of N-nitrosobis(2-hydroxypropyl)amine and N-nitrosobis(2-oxopropyl)amine in MRC rats. J Natl Cancer Inst 1979;63:181–190.
  17. Lijinsky W: Species differences in nitrosamine carcinogenesis. J Cancer Res Clin Oncol 1984;108:46–55.
  18. Gingell R, Wallcave L, Nagel D, Kupper R, Pour P: Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2-hydroxypropyl)amine in the Syrian hamster. J Natl Cancer Inst 1976;57:1175–1178.
  19. Gingell R, Pour P: Metabolism of the pancreatic carcinogen N-nitroso-bis(2-oxopropyl)amine after oral and intraperitoneal administration to Syrian golden hamsters. J Natl Cancer Inst 1978;60:911–913.
  20. Mori Y, Yamazaki H, Toyoshi K, Makino T, Obara T, Yokose Y, Konishi Y: Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: Evidence for a cytochrome P-450 dependent reaction. Carcinogenesis 1985;6:415–420.
  21. Hasler JA: Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999;20:12–24, 25–137.
  22. Guengerich FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106:161–182.
  23. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ: A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991;12:1197–1201.
  24. Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1–21.
  25. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ: Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 1990;87:4790–4793.
  26. Shimada T, Iwasaki M, Martin MV, Guengerich FP: Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 1989;49:3218–3228.
  27. Howard PC, Aoyama T, Bauer SL, Gelboin HV, Gonzalez FJ: The metabolism of 1-nitropyrene by human cytochromes P450. Carcinogenesis 1990;11:1539–1542.
  28. Silvers KJ, Chazinski T, McManus ME, Bauer SL, Gonzalez FJ, Gelboin HV, Maurel P, Howard PC: Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. Cancer Res 1992;52:6237–6243.
  29. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP: Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989;28:4993–4999.
  30. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442–447.
  31. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54–59.
  32. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9 [published erratum in Biochem Biophys Res Commun 1991; 180:1527]. Biochem Biophys Res Commun 1991;175:1112–1118.
  33. Waxman DJ: Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy – a review. Cancer Res 1990;50:6449–6454.
  34. Shea TC, Kelley SL, Henner WD: Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines. Cancer Res 1988;48:527–533.
  35. Whalen R, Boyer TD: Human glutathione S-transferases. Semin Liver Dis 1998;18:345–358.
  36. Juronen E, Tasa G, Uuskula M, Pooga M, Mikelsaar AV: Purification, characterization and tissue distribution of human class theta glutathione S-transferase T1-1. Biochem Mol Biol Int 1996;39:21–29.
  37. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300(Pt 1):271–276.
  38. Foster JR, Idle JR, Hardwick JP, Bars R, Scott P, Braganza JM: Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol 1993;169:457–463.
  39. Clarke J, Flatt PR, Barnett CR: Cytochrome P450 1A-like proteins expressed in the islets of Langerhans and altered pancreatic beta-cell secretory responsiveness. Br J Pharmacol 1997;121:389–394.
  40. Moore MA, Makino T, Tsuchida S, Sato K, Ichihara A, Amelizad Z, Oesch F, Konishi Y: Altered drug metabolizing potential of acinar cell lesions induced in rat pancreas by hydroxyaminoquinoline 1-oxide. Carcinogenesis 1987;8:1089–1094.
  41. Moore MA, Bannasch P, Satoh T, Hacker HJ, Ito N: Immunohistochemically demonstrated increase in glutathione S-transferase species in propylnitrosamine-induced focal proliferative and neoplastic Syrian hamster pancreatic lesions. Virchows Arch B Cell Pathol Incl Mol Pathol 1987;52:479–488.
  42. March TH, Jeffery EH, Wallig MA: Characterization of rat pancreatic glutathione S-transferases by chromatofocusing, reverse-phase high-performance liquid chromatography, and immunohistochemistry. Pancreas 1998;17:217–228.
  43. Hudson CE, DeHaven JE, Schulte BA, Norris JS: Exogenous 17beta-estradiol blocks alpha and mu but not pi class glutathione S-transferase immunoreactivity in epithelium of Syrian hamster vas deferens. J Histochem Cytochem 1999;47:91–98.
  44. Scarpelli DG, Kokkinakis DM, Rao MS, Subbarao V, Luetteke N, Hollenberg PF: Metabolism of the pancreatic carcinogen N-nitroso-2,6-dimethylmorpholine by hamster liver and component cells of pancreas. Cancer Res 1982;42:5089–5095.
  45. Lawson T, Kolar C, Garrels R, Kirchmann E, Nagel D: The activation of 3H-labeled N-nitrosobis(2-oxopropyl)amine by isolated hamster pancreas cells. J Cancer Res Clin Oncol 1989;115:47–52.
  46. Bockman DE, Black O Jr, Mills LR, Webster PD: Origin of tubular complexes developing during induction of pancreatic adenocarcinoma by 7,12-dimethylbenz(a)anthracene. Am J Pathol 1978;90:645–658.
  47. Kawabata TT, Wick DG, Guengerich FP, Baron J: Immunohistochemical localization of carcinogen-metabolizing enzymes within the rat and hamster exocrine pancreas. Cancer Res 1984;44:215–223.
  48. Fujita K, Kamataki T: Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: Application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res 2001;483:35–41.
  49. Pour PM, Weide L, Liu G, Kazakoff K, Scheetz M, Toshkov I, Ikematsu Y, Fienhold MA, Sanger W: Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Am J Pathol 1997;150:2167–2180.
  50. Pour PM, Kazakoff K, Carlson K: Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin. Cancer Res 1990;50:1634–1639.
  51. Pour PM, Kazakoff K: Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol 1996;149:1017–1025.
  52. Bell RH Jr, Pour PM: Pancreatic carcinogenicity of N-nitrosobis(2-oxopropyl)-amine in diabetic and non-diabetic Chinese hamsters. Cancer Lett 1987;34:221–230.
  53. Kokkinakis DM, Scarpelli DG, Subbarao V, Hollenberg PF: Species differences in the metabolism of N-nitroso(2-hydroxypropyl)(2- oxopropyl)amine. Carcinogenesis 1987;8:295–303.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50